Keyphrases
Synergize
100%
TORC1
100%
Mature B-cell Neoplasms
100%
Entinostat
100%
Class I HDAC Inhibitors
100%
Cyclin D
66%
Sirolimus
66%
Burkitt Lymphoma
66%
Mantle Cell Lymphoma
66%
Plasmacytoma
66%
Multiple Myeloma
33%
Histone Deacetylase Inhibitor (HDACi)
33%
Apoptosis
33%
Patient Samples
33%
Negative Regulator
33%
Deregulation
33%
Cancer Cells
33%
Tumor Microenvironment
33%
MTOR Pathway
33%
Minimal Impact
33%
Healthy Donors
33%
Donor Cells
33%
Lymphoma Cells
33%
Cancer Progression
33%
Critical Growth
33%
Co-culture System
33%
Lymphoid Malignancies
33%
Multiple Myeloma Patients
33%
MTOR Inhibitor
33%
Bcl-xL
33%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
33%
Screening Approach
33%
Cell Cycle Arrest
33%
Proliferative Signaling
33%
Highly Active
33%
Cell Cycle Regulation
33%
Myeloma Cells
33%
BIRC5
33%
Mitogenic Signaling
33%
CDKN1A
33%
Retinoblastoma Pathway
33%
Medicine and Dentistry
Neoplasm
100%
Histone Deacetylase Inhibitor
100%
B Cell
100%
Entinostat
100%
Rapamycin
66%
Multiple Myeloma
66%
Cyclin D
66%
Burkitt's Lymphoma
66%
Plasmacytoma
66%
Cell Cycle
33%
P21
33%
Cell Cycle Arrest
33%
Programmed Cell Death
33%
Cancer Growth
33%
Lymphoma
33%
Cancer Cell
33%
Mammalian Target of Rapamycin Inhibitor
33%
Tumor Microenvironment
33%
Retinoblastoma
33%
Cell Cycle Regulation
33%
P16
33%
Mantle Cell Lymphoma
33%
Cell Cycle Checkpoint
33%
Mammalian Target of Rapamycin
33%
Multiple Myeloma Cell Line
33%
Mantle Cell Lymphoma Cell Line
33%
Mitogen-Activated Protein Kinase
33%
Clinical Pathway
33%
Pharmacology, Toxicology and Pharmaceutical Science
Histone Deacetylase Inhibitor
100%
Neoplasm
100%
Multiple Myeloma
100%
Entinostat
100%
Cyclin D
66%
Burkitt's Lymphoma
66%
Rapamycin
66%
Mantle Cell Lymphoma
66%
Plasmacytoma
66%
Malignant Neoplasm
33%
Cancer Growth
33%
Mammalian Target of Rapamycin Inhibitor
33%
Tumor Microenvironment
33%
Lymphoma
33%
Retinoblastoma
33%